Kasvu Therapeutics Raises EUR 30 Million for a Depression Drug Without the Psychedelic Effect

Kasvu Therapeutics, a Helsinki-based biotech, has raised EUR 30 million, roughly $34 million, in a Series A round led by Hadean Ventures, with participation from Tesi (Finnish Industry Investment), Innovestor Life Science Fund, Finnish Drug Discovery Center, Stephen Industries, Nordic Science Investments, and Helsinki University Funds. The round, announced September 24, 2026, is described as the largest funding round to date for a Finnish preclinical-stage pharmaceutical company.

The Science Behind the Round

Kasvu is developing KTX-0141, a small-molecule TrkB potentiator designed to reproduce the antidepressant and neuroplasticity benefits associated with psychedelic compounds, without activating the 5-HT2A receptor responsible for their hallucinogenic effects. The approach targets the brain's BDNF and TrkB signaling pathway directly, a research direction that grew out of University of Helsinki neuroscience work and became the basis for the company's founding in 2023.

Why Removing the Hallucinogenic Effect Matters

Psychedelic-derived compounds have shown real promise in depression research over the past decade, but their hallucinogenic properties create significant clinical hurdles: patients typically require supervised dosing sessions lasting hours, specialized clinical settings, and trained staff to manage the psychoactive experience, all of which limit how broadly such a treatment could ever be prescribed even if approved. A compound that delivers comparable neuroplasticity benefits without the trip removes nearly all of that infrastructure burden, potentially making a TrkB-targeted antidepressant prescribable in a conventional outpatient setting, closer to how existing antidepressants are already used.

What the Funding Covers

The EUR 30 million will fund IND and clinical trial application-enabling work along with Phase I and Phase Ib trials in major depressive disorder, with human trials targeted to begin in the second half of 2027. That timeline reflects a preclinical-stage company still roughly a year from its first human dosing, a normal cadence for a small-molecule CNS drug but one that leaves meaningful scientific and regulatory risk ahead before KTX-0141's real-world efficacy is known.

A Notably Deep, Nordic-Anchored Investor Base

The investor syndicate is unusually concentrated in Finnish and Nordic life-science capital, from Tesi's government-linked industrial investment mandate to Helsinki University's own funding vehicle, a sign of a domestic ecosystem willing to back a preclinical biotech at meaningful scale rather than the company needing to look primarily to larger US or broader European life-science funds for its first major round.

What This Means for Founders

For founders building in neuroscience, psychiatry, or drug discovery, Kasvu's round is a reminder that investor appetite for differentiated CNS mechanisms remains strong even at the preclinical stage, provided the underlying science offers a clear practical advantage, here, removing a major clinical deployment barrier, over existing approaches in the same therapeutic space. A large domestic investor base backing a record round also signals that strong regional life-science ecosystems outside the US and UK can fund ambitious preclinical work without requiring an early cross-border raise.

Founders building in biotech or life sciences can find active investors through the match tool, browse biotech investors in the directory, or check the live listing of current opportunities. Catch up on more coverage in the newsroom, or register on AngelLinx to start a raise.

AngelLinx Intelligence | angellinx.ai